Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
Marthe Kirkesæther Brun, Guro Løvik Goll, Kristin Kaasen Jørgensen, et al.
Journal of Internal Medicine (2022) Vol. 292, Iss. 3, pp. 477-491
Open Access | Times Cited: 25

Showing 25 citing articles:

HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis
Virginia Solitano, Antonio Facciorusso, Dermot McGovern, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 12, pp. 3019-3029.e5
Open Access | Times Cited: 24
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Marthe Kirkesæther Brun, Johanna Elin Gehin, K. H. Bjørlykke, et al.
The Lancet Rheumatology (2024) Vol. 6, Iss. 4, pp. e226-e236
Closed Access | Times Cited: 7
Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies
Isabella J. Tan, Alicia Podwójniak, Aarushi K. Parikh, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 4, pp. 2975-2990
Open Access | Times Cited: 7
Obesity and tobacco smoking are independently associated with poor patient-reported outcomes in SLE: a cross-sectional study
Alvaro Gómez, Ioannis Parodis, Christopher Sjöwall
Rheumatology International (2024) Vol. 44, Iss. 5, pp. 851-861
Open Access | Times Cited: 5
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 291-308
Closed Access | Times Cited: 5
Assessing early therapeutic drug monitoring of adalimumab as a predictor of treatment efficacy and immunogenicity in rheumatic diseases: “early therapeutic drug monitoring of adalimumab”
Patricia Ortiz-Fernández, Carles Iniesta Navalón, Elena Urbieta-Sanz, et al.
Clinical Rheumatology (2025)
Open Access
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, et al.
BioDrugs (2022) Vol. 36, Iss. 6, pp. 731-748
Open Access | Times Cited: 23
Precision medicine in inflammatory bowel disease
Zhen Zeng, Mingshan Jiang, Xi Li, et al.
Precision Clinical Medicine (2023) Vol. 6, Iss. 4
Open Access | Times Cited: 11
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
Julia Husman, Karin Černá, Katja Matthes, et al.
International Journal of Colorectal Disease (2024) Vol. 39, Iss. 1
Open Access | Times Cited: 3
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Ingrid Jyssum, Johanna Elin Gehin, Joseph Sexton, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 6, pp. 1746-1755
Open Access | Times Cited: 9
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations
Ole Haagen Nielsen, Alexander Hammerhøj, Mark Ainsworth, et al.
Drugs (2024)
Closed Access | Times Cited: 2
HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases
Marthe Kirkesæther Brun, K. H. Bjørlykke, Marte K. Viken, et al.
Journal of Internal Medicine (2023) Vol. 293, Iss. 5, pp. 648-655
Open Access | Times Cited: 6
Effect of the extended dosing interval of anti-TNF-α NANOBODY® compound ozoralizumab in patients with low disease activity rheumatoid arthritis
Tsutomu Takeuchi, Megumi Nakanishi, Masafumi Kawanishi, et al.
Modern Rheumatology (2023) Vol. 34, Iss. 4, pp. 678-685
Open Access | Times Cited: 4
Complementary Therapeutic Effect of Fecal Microbiota Transplantation in Ulcerative Colitis after the Response to Anti-Tumor Necrosis Factor Alpha Agent Was Lost: A Case Report
Jongbeom Shin, Ga Hyeon Baek, Boram Cha, et al.
Biomedicines (2024) Vol. 12, Iss. 4, pp. 800-800
Open Access | Times Cited: 1
Harnessing Variability Signatures and Biological Noise May Enhance Immunotherapies’ Efficacy and Act as Novel Biomarkers for Diagnosing and Monitoring Immune-Associated Disorders
Tal Sigawi, A Israeli, Yaron Ilan
ImmunoTargets and Therapy (2024) Vol. Volume 13, pp. 525-539
Open Access | Times Cited: 1
Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases
Silje Watterdal Syversen, Johanna Elin Gehin, Guro Løvik Goll, et al.
Arthritis & Rheumatology (2023) Vol. 76, Iss. 5, pp. 667-669
Open Access | Times Cited: 3
Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study
Brigitte Michelsen, Kristine Thomassen Berget, Arthur Kavanaugh, et al.
Rheumatology and Therapy (2022) Vol. 9, Iss. 4, pp. 1171-1179
Open Access | Times Cited: 4
Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study
Rodrigo Bremer Nones, Eron Fábio Miranda, Gustavo de Nardi Marçal, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 7, pp. 711-720
Closed Access
Adalimumab Autoantibodies in Uveitis Patients: Do We Need Routine Drug Monitoring?
Lynn S. zur Bonsen, Vitus A. Knecht, Anne Rübsam, et al.
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2782-2782
Open Access
Detection of Antibodies to Infliximab in routine care: a 4-year French retrospective study
Daniel Bertin, Jehanne Aghzadi, Nathalie Balandraud, et al.
Clinical & Experimental Immunology (2024)
Open Access
Therapeutic Drug Monitoring in Patients with Ulcerative Colitis on Infliximab: A Cost-Effectiveness Analysis
Paul Dupenloup, Margaret Zhou, Matthew P. Dizon, et al.
Digestive Diseases and Sciences (2024)
Closed Access
The Biosimilar CT-P13 Infliximab Is More Immunogenic Than the Original Infliximab In Iraqi Patients with Ankylosing Spondylitis
Mohammed Mahmood Kamil, Nizar Abdulateef Jasim, Mohammed Abdul-Hassan Jabarah AL-Zobaidy
The Egyptian Journal of Hospital Medicine (2022) Vol. 89, Iss. 1, pp. 5632-5638
Open Access | Times Cited: 1
Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics
Mohammed M. Kamil, Mohammed Abdul- Hassan Jabarah, Nizar A.l. Jasim
Journal of the Faculty of Medicine Baghdad (2023) Vol. 64, Iss. 4
Open Access
Infliximab serum concentrations in luminal Crohn's disease and its relationship with disease activity: A multicentric cross-sectional study
Rodrigo Bremer Nones, Eron Fábio Miranda, Gustavo de Nardi Marçal, et al.
Gastroenterología y Hepatología (2023) Vol. 47, Iss. 7, pp. 711-720
Closed Access
Page 1

Scroll to top